Navigation Links
Studies assess genetics, modified treatment to improve outcomes, reduce toxicity
Date:12/8/2012

a treatment associated with both short- and long-term toxicities.

ALL, the most common form of leukemia in children, is a fast-growing cancer of the white blood cells in which the bone marrow makes a large number of abnormal white blood cells that are unable to develop and fight infection. Important developments over the past 20 years have led to seminal insights about ALL in children, and today nearly 90 percent of children diagnosed with standard-risk ALL are cured. Some treatment regimens for standard-risk ALL include initial infusions of daunorubicin, a type of anthracycline. While effective, continual use of this therapy is associated with potential long-term heart damage, leading researchers to assess whether eliminating or reducing the dosage of daunorubicin during the initial one-month induction therapy period might provide the same level of efficacy as the standard treatment protocol with reduced long-term risk.

In order to assess the efficacy of ALL treatment without daunorubicin during induction therapy, a team of researchers from 20 centers across France and one center in Belgium initiated a multicenter Phase III clinical trial in which 1,128 pediatric patients with standard-risk B-cell ALL were randomized into two treatment arms. Arm A included 560 patients who received a standard dose of daunorubicin during induction therapy, while Arm B included 568 patients who did not receive initial therapy with daunorubicin. Both groups received doxorubicin during delayed intensification (last treatment phase before reaching maintenance) and a standard protocol of 24-month maintenance therapy from December 2000 to June 2010, during which five-year event-free survival (EFS) and overall survival (OS) were assessed.

For those patients treated with daunorubicin, the five-year EFS rate was 92.9 percent, compared to 93.3 percent in the non-daunorubicin arm. Overall survival rates were 97.2 percent and 98.2 percent in the daunorubicin and n
'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
614-352-5096
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. John Theurer Cancer Center to present 37 studies at the 2012 ASH Annual Meeting
2. Benefit6 Whole Body Protection, a New Product by I Do Strive LLC, Provides Increased Energy Production According to Recent Studies
3. Sharp spike in computer-related injuries predicted for medical workers, find studies
4. Analysis of conflicting fish oil studies finds that omega-3 fatty acids still matter
5. Studies from 2012 Quality Care Symposium highlight findings in improving quality of cancer care
6. New studies show effects of mammography guideline changes
7. 2 NIH studies show power of epidemiology research; Underscore need to address health disparities
8. Scripps studies show community-based diabetes programs are key to lowered costs and improved care
9. Cancer Drug Reduced Relapses in MS Patients: Studies
10. University of Houston India Studies Program presents Circuits of Empire: India as Metropole
11. Studies Show Limits, Promise of Laser Removal of Tattoos
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... Chicago, IL (PRWEB) March 29, 2015 ... Foundation for Women’s Cancer announce today that ... 2015 recipient of the Claudia Cohen Research Foundation Prize ... presented at the Society of Gynecologic Oncology 46th Annual ... is Director of the Cedars-Sinai Women’s Cancer Program at ...
(Date:3/29/2015)... 2015 Final Cut Pro X ... Pixel Film Studios, entitled TranSports. , “TranSports is ... Final Cut Pro X,” said Christiana Austin, CEO of ... needed to effortlessly transition using this cool sports transition ... and uniquely styled transition pack for Final Cut Pro ...
(Date:3/28/2015)... Tucson, AZ. (PRWEB) March 28, 2015 ... according to a new study by researchers ... (HSPH). , Produced with the support of the Coffee ... the journal Molecular Psychiatry this past fall, the study—one ... a meta-analysis of genomic data from more than 120,000 ...
(Date:3/28/2015)... The California-based leading wig brand UniWigs ... shopping on UniWigs during the Easter Holidays from today ... promotion on April Fools’ Day. , As the winter ... the corner. Easter Festival, with religious origins to countries ... holiday after Christmas. The best wig provider, UniWigs, would ...
(Date:3/28/2015)... Vegas, NV (PRWEB) March 28, 2015 Pitching ... with a history of shoulder and elbow injuries, according to ... Sports Medicine’s ( AOSSM ) Specialty Day. , “Our findings ... with a 20% increase in likelihood of a history of ... associated with a 12% increase likelihood of a history of ...
Breaking Medicine News(10 mins):Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 3Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 4Health News:Introducing TranSports for Final Cut Pro X Users from Pixel Film Studios 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2
... ... parenting tips for teens , ... Washington, DC (Vocus) October 16, 2009 -- More than 30 pediatric experts from Children’s ... Conference and Exhibition, which runs from October 16 – 19 in Washington. , , , ...
... SAN ANTONIO, Oct. 16 The National Trauma Institute, ... in the United States, announced its first Request for ... to change medical practice and save lives. , The ... translational research to take place in 2010. "Historically, trauma ...
... Friday, October 16, U.S. President Barack Obama will join U.S. ... Texas to celebrate the 20th Anniversary of Points of Light ... in their communities. , The anniversary marks President Bush,s inauguration ... of Light" to salute and encourage individuals to solve problems ...
... Pa., Oct. 16 Amgen (Nasdaq: AMGN ) ... scientific data about ENBREL being presented at the 2009 ... Pa., from Oct. 17-21, 2009. These presentations contribute to ... , "The clinical data being presented at ...
... Rotary International has declared October 24, 2009, "World Polio Day" ... In the past 10 years alone Rotarians in Alaska and ... of a polio-free world. They have also traveled to places ... national immunization days. , In 1985, Rotary International joined with ...
... will allow public forum for discussing the latest updates, information on ... of the public are invited to submit questions for inclusion in ... Thursday, Oct. 22, from 10 a.m. - noon on Twitter. ... of Michigan Health System and VA Ann Arbor Healthcare System, will ...
Cached Medicine News:Health News:Children's National Experts Presenting at American Academy of Pediatrics Conference, 2Health News:National Trauma Institute Announces $600,000 in Funding for Trauma Research 2Health News:President Barack Obama Joins President George H.W. Bush to Celebrate the 20th Anniversary of the 'Points of Light' Volunteer Movement and Extend the Call of Service to the Nation 2Health News:President Barack Obama Joins President George H.W. Bush to Celebrate the 20th Anniversary of the 'Points of Light' Volunteer Movement and Extend the Call of Service to the Nation 3Health News:President Barack Obama Joins President George H.W. Bush to Celebrate the 20th Anniversary of the 'Points of Light' Volunteer Movement and Extend the Call of Service to the Nation 4Health News:President Barack Obama Joins President George H.W. Bush to Celebrate the 20th Anniversary of the 'Points of Light' Volunteer Movement and Extend the Call of Service to the Nation 5Health News:President Barack Obama Joins President George H.W. Bush to Celebrate the 20th Anniversary of the 'Points of Light' Volunteer Movement and Extend the Call of Service to the Nation 6Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 2Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 3Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 4Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 5Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 6Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 7Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 8Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 9
(Date:3/27/2015)... , March 27, 2015 ... International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare, ... senior service industry, will be held at Shanghai New ... On 25 February, 2015,  Implementation Suggestions on Encouraging Private ... Industry, which was jointly issued by the Ministry of ...
(Date:3/27/2015)... 2015 According to a new ... (Conventional, Advanced, Ultrasound), Ablation Catheter (Cryoablation, RF, Microwave), Lab ... VT, WPW) - Global Forecasts to 2019 ", published by ... around ~$4.73 Billion by 2019 with a CAGR of ... Browse   90   ma ...
(Date:3/27/2015)... DALLAS , March 27, 2015   ... global leader in biosimilars and the world,s leading ... two studies that support an evaluation of biosimilarity ... U.S. Food and Drug Administration (FDA) conditionally approved ... Amgen,s EPOGEN™ (epoetin alfa). These study data were ...
Breaking Medicine Technology:CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 2CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 3CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 4CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 5CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 6Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3
... DIEGO, Oct. 19 Ceregene, Inc., a biopharmaceutical company, ... double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in ... that delivers the neurotrophic factor neurturin to degenerating or ... clinical trial of CERE-120 are being published later this ...
... PRGO ; TASE) today announced that it will release ... November 2, 2010 at approximately 8:00 a.m. (ET).  The Company ... by Joseph C. Papa, Perrigo,s Chairman and Chief Executive Officer. ... webcast to interested parties on the Perrigo website http://www.perrigo.com ...
Cached Medicine Technology:Ceregene Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinson's Disease 2Ceregene Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinson's Disease 3Ceregene Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinson's Disease 4Ceregene Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinson's Disease 5
... gentle and effective surgical scrub with special ... is known to kill skin surface pathogens, ... protozoa and yeasts. It produces a rich ... pre-operative prepping, as well as for pre-and ...
... Aplicare two and four ounce ... meet the needs of procedural ... bottle itself has been custom ... match the cap perfectly. This ...
A patient skin prepping solution in a self-contained applicator combining two proven broad-spectrum antimicrobials: alcohol for fast kill and fast drying (3 minutes on skin), and an iodophor for pers...
Idophor PVP Scrub Winged Sponges...
Medicine Products: